5,326 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 5,326 shares of the company’s stock, valued at approximately $252,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mather Group LLC. purchased a new position in shares of Ionis Pharmaceuticals during the 1st quarter valued at $29,000. nVerses Capital LLC acquired a new position in Ionis Pharmaceuticals in the 2nd quarter worth about $29,000. Sunbelt Securities Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the 1st quarter worth about $44,000. Advisors Asset Management Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 948.8% during the 1st quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company’s stock valued at $138,000 after buying an additional 2,875 shares during the last quarter. Finally, Checchi Capital Advisers LLC bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Richard S. Geary sold 2,430 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.00, for a total value of $116,640.00. Following the sale, the executive vice president now owns 85,508 shares of the company’s stock, valued at $4,104,384. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Richard S. Geary sold 2,430 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $48.00, for a total value of $116,640.00. Following the sale, the executive vice president now owns 85,508 shares of the company’s stock, valued at $4,104,384. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Joseph Klein III sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $50.00, for a total transaction of $600,000.00. Following the transaction, the director now owns 16,346 shares of the company’s stock, valued at approximately $817,300. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,750 shares of company stock valued at $732,371 over the last ninety days. 2.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IONS shares. Barclays raised their price objective on shares of Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. The Goldman Sachs Group lifted their price objective on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the company a “sell” rating in a research note on Friday, August 2nd. Guggenheim raised their target price on Ionis Pharmaceuticals from $64.00 to $70.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Jefferies Financial Group assumed coverage on Ionis Pharmaceuticals in a research report on Tuesday, July 16th. They issued a “buy” rating and a $75.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.56.

Ionis Pharmaceuticals Stock Up 0.3 %

Shares of IONS opened at $37.91 on Friday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 7.51 and a current ratio of 7.61. The company has a 50-day simple moving average of $45.52 and a 200-day simple moving average of $43.62. Ionis Pharmaceuticals, Inc. has a 52 week low of $35.95 and a 52 week high of $54.44. The firm has a market capitalization of $5.53 billion, a P/E ratio of -14.15 and a beta of 0.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The firm had revenue of $225.00 million during the quarter, compared to analysts’ expectations of $152.35 million. During the same quarter in the prior year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 19.7% on a year-over-year basis. On average, equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 earnings per share for the current year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.